MTNB

Matinas is not a going concern in any meaningful sense — management states plainly that cash on hand is insufficient to fund operations beyond twelve months from the filing date and that 'substantial doubt exists about our ability to continue as a going concern.' After the October 2024 collapse of its MAT2203 partnership talks, the company cut 80% of its workforce (15 positions, including three senior managers) and paused clinical development of its lead and effectively only asset. R&D expense cratered 99.3% to $85K in FY2025 — the clearest possible signal that this is no longer a drug developer but a shell searching for a partner, a reverse merger, or, in management's own words, 'a potential winddown or dissolution of the Company.' There is no product, no revenue (zero in both FY2024 and FY2025), and no pipeline being actively advanced.

The numbers underneath are a burning fuse. FY2025 net loss was $10.3M against just $4.0M of cash; operating cash burn was $7.0M. The $3.3M raised via the February 2025 Series C preferred deal is a fraction of annual burn and comes attached to ~11.3M warrants and preferred convertible at $0.586 — against only 6.41M shares outstanding today. Conversion and warrant exercise would multiply the share count several-fold, and the accumulated deficit of $211M underscores two decades of value destruction. Book equity of $4.83M is almost entirely a $4.0M cash balance that is being spent down; total assets fell 43% year over year. The 'improved' loss and margin figures are simply the arithmetic of switching off the lights, not a turnaround.